Open Nav

Tradewind BioScience, Inc.

Networking, partnering

  • Date:Thursday, October 18
  • Time:11:15 AM - 11:30 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Tradewind is an early stage therapeutics company dedicated to attacking metastatic cancers in new ways. We are currently advancing an antibody therapeutic for ovarian cancer that will treat primary malignancy, existing metastasis and prevent further spread. When highly expressed, our pro-metastatic target predicts for poor patient survival in ovarian and other cancers. Recently, however, it has been confirmed using a genetically engineered mouse model that it is a potent initiating oncogene in the ovary. It has a role in early to late stage ovarian cancer making this an ideal first indication. In vivo, our prototype therapeutic produces a pronounced anticancer effect in several models with no toxicities being noted.
  • Company Website:
  • Company HQ City:Daly City
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Thaddeus Allen
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Antibody therapeutic for ovarian cancer
  • Development Phase of Primary Product:Discovery
  • Previous and Current Investors:Y Combinatory, various angel investors
  • Size of Last Investment Round:$240,000
  • Total Amount Raised to Date, In All Rounds:$240,000